key: cord-0833054-jewcgjje
authors: Gumussu, Kevser; Erhan, Belgin
title: Spasticity management of individuals with spinal cord injury in era of societal restrictions due to COVID 19 pandemic
date: 2021-01-31
journal: Toxicon
DOI: 10.1016/j.toxicon.2020.11.402
sha: 93ba27e6b209fa5addc60f6900594b7c4e18d31b
doc_id: 833054
cord_uid: jewcgjje

nan

Introduction: Poststroke spasticity is common and very disabling. This study aims to compare the number of muscles targeted and therapeutic results of different formulations of botulinum toxin type A used in real-life management of poststroke spasticity. Methods: A sample of 216 patients (108 females) with poststroke spasticity was divided into 2 groups: on-label dose (Group 1) and over-thelabel dose (Group 2). Each group was categorized by gender, age, BoNT-A formulation used (abobotulinumtoxinA [ABO]), incobotulinumtoxinA [INCO] ), and onabotulinumtoxinA [ONA]), treatment outcomes (evaluated with Goal Attainment Scale [GAS] ), and number of muscles injected per session. A total of 2083 treatment sessions were evaluated. On-label doses considered were: ABO 1500 U, ONA 400 U, and INCO 500 U. Treatment success was defined as a GAS score 0 per goal. Results: Group 2 patients were treated in more upper limb muscles than Group 1 (ABO Group 1 vs Group 2: 5.17 ± 2.46 vs 6.89 ± 1.95, P<0.001; ONA Group 1 vs Group 2: 3.98 ± 2.62 vs 5.93 ± 2.12, P <0.001; INCO Group 1 vs Group 2: 4.59 ± 2.78 vs 6.83 ± 2.37, P <0.001), as well as in lower limb muscles (ABO Group 1 vs Group 2: 3.08 ± 2.32 vs 5.21 ± 2.15, P <0.001; ONA Group 1 vs Group 2: 2.14 ± 2.27 vs 4.78 ± 1.79, P <0.001; INCO Group 1 vs Group 2: 2.92 ± 2.55 vs 4.69 ± 1.49, P <0.001). A comparison of treatment outcomes, showed no difference between groups, independent of the formulations used (ABO Group 1 vs Group 2: X 2 (1) ¼ 0.071, P ¼0.79; ONA Group 1 vs Group 2: X 2 (1) ¼ 0.259, P ¼0.61; INCO Group 1 vs Group 2: X 2 (1) ¼ 0.10, P ¼0.92). Conclusion: Our data suggest that higher total doses allowed clinicians to increase the number of targeted muscles per limb in selected cases. On the other hand, Group 2 showed the same treatment success rate as Group 1. Hence, if Group 2 had received lower total doses it would mean either fewer muscles treated or lower doses per muscle, with predictably lower rates of success, ie, the use of over-the-label doses was worthwhile. Keywords: Botulinum Toxin; GAS score; Poststroke spasticity; Targeted Introduction: With the emergence of the novel coronavirus (SARS-CoV-2), the COVID-19 pandemic has swept the world and left us with serious public health concerns and the need for significant modifications in healthcare operations all around the globe. These unprecedented times have been hard for everyone with or without disability; however, we feel that there has been a serious lack of information targeted specifically to spinal cordeinjured (SCI) individuals. Inaccessibility to hospitals or health care systems for their routine follow up visits and treatments and psychological distress due to quarantine measures are among the common problems that persons with SCI may face during the COVID-19 pandemic. Most of the outpatient services, including botulinum toxin type A (BoNT-A) injections for the management of spasticity, were postponed. 1 We aimed to study the spasticity management and activities of daily living of individuals who have spasticity due to SCI in this socially restricted era. Methods: A telephone interview was conducted with individuals with SCI who had moderate and severe spasticity. Twenty-four volunteers participated in this cross-sectional study. All of the patients received ultrasoundguided BoNT-A injections at two rehabilitation centers in Istanbul, between 15th September, 2019 and 15th March, 2020. A questionnaire prepared by the authors was used and all participants were interviewed by the same author (KG) between 15th June and 15th July, 2020. Each participant was asked about increases in spasticity during the societal restrictions of the COVID-19 pandemic and the need for a new BoNT-A injection. The spasticity severity of the previous week was rated on a numeric rating scale (NRS). Activities of daily living complicated by spasticity were addressed with open-ended questions. Accessibility to the health care system and medications was also queried. Results: The demographic characteristics of the 24 participants are summarized in Table 1 . Eighteen (75%) patients reported a moderate increase in spasticity, while 3 (12.5%) patients reported a severe increase and 3 (12.5%) reported no difference during this time period. The m ean NRS score was 6 (±2). Twenty-one (87.5%) of the patients reported a need for BoNT-A treatment because of symptom re-emergence. In relation to spasticity-induced deterioration in activities of daily living, 10 (42%) individuals reported difficulty in walking. Ten (42%) patients reported difficulty in sitting in the wheelchair, and 11 (46%) experienced lack of sleep due to spasticity symptoms. Thirteen (54.2%) of the patients had difficulty with keeping doctors' appointments. All of the patients reported that they obtained their medications easily. Conclusions: Most (87.7%) of the individuals with SCI reported a moderate or severe increase in spasticity due to the societal restrictions enforced to cope with the COVID-19 pandemic. Spasticity also affected their activities of daily living. During the pandemic, the global and local health authorities have neglected people with SCI and other disabilities to some degree. 2 People with disabilities are a vulnerable group and deserve more attention in extraordinary conditions such as pandemics, hurricanes, or earthquakes. Introduction and Objectives: The aim of the study was to analyse the influence of the course of severity of idiopathic cervical dystonia (CD) before botulinum toxin (BoNT) on long-term outcome of BoNT therapy. Methods: Seventy-two CD patients who were treated on a regular basis in the botulinum toxin outpatient department of the University of Düsseldorf and had received at least 3 injections were consecutively recruited after written informed consent was obtained. While waiting for their next injection patients had to rate the amount of improvement of CD in percent of severity of CD at start of BoNT therapy (IMP). Then they had to draw the course of severity of CD (CoD graph) from onset of symptoms until the start of BoNT therapy in a 10x10cm square. The residual CD severity was estimated by the treating physician using the Tsui score. Demographic and treatment-related data were extracted from the charts of the patients. Results: Depending on the curvature, three different types of CoD graphs could be distinguished. Time to BoNT therapy, severity of CD at start of BoNT therapy, dose used at start of therapy, increase of dose during therapy, and outcome (IMP) were significantly different (P<0.05) when patients were split up according to these three different graph types. Patients with a more rapid development of CD responded better although lower doses were used. Conclusions: The course of severity of CD before BoNT therapy influences the long-term outcome. This has implications for patient management and information on the efficacy of BoNT therapy. Introduction: Spasticity-related pain (SRP) in children and adolescents with cerebral palsy (CP) is common, often neglected, and impacts daily quality of life. We assessed the effect of incobotulinumtoxinA on SRP using pooled data from 3 large Phase 3 pediatric studies. Methods: Ambulant and non-ambulant patients (2-17 years of age; uni-or bilateral CP; Ashworth Scale score 2 in clinical patterns for treatment) were enrolled. Patients received total body incobotulinumtoxinA doses of 16 U/kg (400 U) for lower-limb (LL) treatment in 2 injection cycles (ICs) in TIM (NCT01893411). In TIMO (NCT01905683), TIM completers and new recruits received 4 ICs with 16-20 U/kg (400-500 U) for LL or combined LL and upper-limb (UL) treatment. In XARA (NCT02002884), patients received 4 ICs with 16-20 U/kg (400e500 U) for UL or combined LL/UL treatment. Changes in self-reported (child/adolescent) or observed (parent/caregiver) SRP were assessed using the Questionnaire on Pain caused by Spasticity (QPS) in patients with LL (TIM, TIMO, and XARA) and UL treatment (TIMO and XARA). 

Michael Althaus e , Marta Banach f , Deborah Gaebler-Spira g . a Division of Paediatric Neurology and Developmental Medicine and LMU Center for Children With Medical Complexity, Dr. von Hauner Children's Hospital

Department of Paediatrics e Dr. von Hauner Children's Hospital, Division of Paediatric Neurology & Developmental Medicine and LMU Center for Children with Medical Complexity, Dr. von Hauner Children's Hospital